Bellbrook Labs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Biochemical assays for key enzymes in the innate immunity and DNA damage response (DDR) pathways

Editorial Article: 7 lab products advancing drug discovery Take a look at what other researchers and scientists are saying about cutting-edge technologies in drug discovery 28 Apr 2021 Here at SelectScience, our goal has always been to provide scientists worldwide with the information they need to make the best purchasing decisions to advance their work. But we couldn't do that without the support and input of our vast community of reviewers. Here, as part of our new Advances in Drug Discovery Special Feature, we’ve collated a selection of our favorite reviews of the technologies involved i...

Industry News: BellBrook Labs receive NIH grant to treat lupus and related autoimmune diseases The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway 22 Apr 2021 BellBrook Labs has been awarded a $1.8 million Phase II SBIR grant by the National Institute of Allergy and Infectious Diseases (NIAID) to develop lead molecules that block cyclic GAMP synthase (cGAS) for the treatment of lupus and other autoimmune diseases.  BellBrook’s CEO, Dr. Robert Lowery is the principal investigator for the effort, and Dr. Keith Elkon...

Industry News: BellBrook Labs receives NIH funding for novel approach to stimulating anti-tumor immunity 12 Mar 2021 BellBrook Labs has been awarded a $300,000 Phase I Small Business Innovative Research (SBIR) grant to develop and validate HTS assays for the discovery of small-molecule antagonists of TREX1. Immunotherapy approaches such as immune checkpoint blockade are transforming oncology.  However, many patients do not respond to existing agents, and new therapeutic strategies for eliciting immune responses to tumors are badly needed.  It has recently become clear that activation of the...

Product News: TR-FRET readout now available with the Transcreener cGAMP cGAS Assay With this addition, researchers can more easily screen for small molecule modulators of cGAS 26 Jan 2021 Launched in November 2019, the Transcreener cGAMP cGAS Assay has generated a great deal of interest in the drug discovery community. While fluorescence polarization (FP) readouts offer a stable and robust option, some researchers prefer time-resolved Förster-resonance-energy-transfer (TR-FRET) readouts for large screens. After months of development, BellBrook Labs is pleased to announce the addition of a TR...